Topical cyclosporine 0.05% impact on pterygium recurrence in patients undergoing pterygium surgery

Evaluation of topical cyclosporine 0.05% impact on pterygium recurrence in patients undergoing pterygium surgery in Amiralmomenin Hospital, Rasht

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160919029871N4

Enrollment

Registered

2019-09-28

Start date

2019-09-23

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pterygium. Pterygium of eye

Interventions

Intervention 1: Intervention group: Aside from the routine topical Bethamethasone and Antibiotic drops the intervention group will receive topical drops of cyclosporine (0.0.5%) for 3 months. Interven

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with a Pterygium larger than 3 mm at horizontal width over the cornea on Slit-lamp exam who are candidates for surgery

Exclusion criteria

Exclusion criteria: Patients with previous pterygium recurrence, pseudo-pterygium Pregnant and breastfeeding mothers, systemic disease like diabetes and heart disease Ocular surface disease like keratitis or dry eye or conjunctivitis Prior ocular surgery within 6 months Hypersensitivity to cyclosporine

Design outcomes

Primary

Measure	Time frame
Clinical inflammation grading and pterygium recurrence. Timepoint: Day 1, 3, 7, 30, 90 and 6 months after surgery. Method of measurement: Clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mitra Akbari

Guilan University of Medical Sciences

mitra.akbari20@gmail.com+98 13 3323 6886

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026